ProCE Banner Activity

New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Slideset

In these downloadable slides, leading experts discuss the current therapeutic landscape for advanced EGFR-mutated NSCLC, unmet needs in the progressive disease setting, and the promise of novel investigational agents targeting HER3.

Released: December 17, 2024

Expiration: December 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.